SRP3208
IL-3 from mouse
Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Synonym(s):
HCGF, MCGF (Mast cell growth factor), Multi-CSF, P-cell stimulation factor
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352202
NACRES:
NA.32
Recommended Products
biological source
mouse
recombinant
expressed in E. coli
Assay
≥98% (HPLC)
≥98% (SDS-PAGE)
form
lyophilized
potency
≤0.05 ng/mL ED50
mol wt
15.1 kDa
packaging
pkg of 10 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white to off-white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
mouse ... IL3(16187)
General description
IL-3 (interleukin 3) is primarily produced by activated CD4+ T cells and mast cells, and is a multi-lineage hematopoietic growth factor and immunoregulatory cytokine.
Recombinant murine IL-3 is a 15.1 kDa globular protein containing 135 amino acid residues.
Recombinant murine IL-3 is a 15.1 kDa globular protein containing 135 amino acid residues.
Biochem/physiol Actions
IL-3 (interleukin 3) plays a key role in the differentiation of murine hematopoietic progenitor cells and the activation and survival of mature myeloid cells. This protein was originally termed as multicolony-stimulating factor (multi-CSF) because of its capability to induce the differentiation of a wide variety of hematopoietic progenitor cells from bone marrow, such as mast cells, basophils, neutrophils, eosinophils, macrophages, dendritic cells, erythrocytes, and megakaryocytes. IL-3 promotes mast cell growth, differentiation, and mediator release, hence, suggesting a role in allergic inflammation. In mice, it is involved in suppressing protective immunity against Plasmodium berghei NK651, and prevents the development of splenomegaly, anemia, and erythropoiesis. It functions as a regulator of osteoclastogenesis, where it play a dual role- it facilitate the development of osteoclast progenitors but suppresses the osteoclastogenic process.
Sequence
MDTHRLTRTL NCSSIVKEII GKLPEPELKT DDEGPSLRNK SFRRVNLSKF VESQGEVDPE DRYVIKSNLQ KLNCCLPTSA NDSALPGVFI RDLDDFRKKL RFYMVHLNDL ETVLTSRPPQ PASGSVSPNR GTVEC
Physical form
Lyophilized from 0.1% TFA.
Reconstitution
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Huixian Hong et al.
Biochemical and biophysical research communications, 440(4), 545-550 (2013-10-10)
Interleukin (IL)-3, a multilineage hematopoietic growth factor, is implicated in the regulation of osteoclastogenesis. However, the role of IL-3 in osteoclastogenesis remains controversial; whereas early studies showed that IL-3 stimulates osteoclastogenesis, recent investigations demonstrated that IL-3 inhibits osteoclast formation. The
J N Ihle
Chemical immunology, 51, 65-106 (1992-01-01)
Considerable information has accumulated over the past several years relating to the biological activities of IL-3 which supports that concept that IL-3 has a unique capacity to support the proliferation and differentiation of a wide spectrum of hematopoietic cells. The
Serena De Vita et al.
PloS one, 9(5), e96209-e96209 (2014-05-03)
Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of
Jing Wang et al.
EMBO molecular medicine, 6(7), 952-969 (2014-06-26)
Immunoglobulin E (IgE) activates mast cells (MCs). It remains unknown whether IgE also activates other inflammatory cells, and contributes to the pathogenesis of abdominal aortic aneurysms (AAAs). This study demonstrates that CD4+ T cells express IgE receptor FcεR1, at much
Interleukin-3-deficient mice have increased resistance to blood-stage malaria.
Auclair SR et al
Infection and Immunity, 82(3), 1308-1314 (2014)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service